LabGenius’ Research Collaboration with Sanofi Yields Positive Results
Over a multi-year collaboration, LabGenius applied its ML-driven antibody engineering platform to co-optimise NANOBODY® proteins for therapeutically valuable properties.
18th September 2023
Find us in the poster hall at number 5.
LONDON, United Kingdom – 18/09/23. LabGenius, a pioneer in the use of machine learning (ML) for antibody discovery, today presented data in a poster presentation at the Single-Domain Antibodies 2023 Meeting. The presentation debuted data from LabGenius’ antibody discovery platform, confirming that a panel of optimised NANOBODY® candidates met the pre-defined success criteria for the collaboration, whilst also maintaining favourable production characteristics.
In 2021, LabGenius and Sanofi initiated a multi-year collaboration in the area of inflammation that combined LabGenius’ capabilities in machine learning (ML), robotic automation, and synthetic biology with Sanofi’s expertise in the therapeutic development of NANOBODY® heavy chain variable domains.
In the readout of results, LabGenius confirmed that the 10 most improved NANOBODY® variants demonstrated up to a 7-fold improvement in the desired property of interest, whilst maintaining the potency of the starting molecule. All variants also expressed well in Escherichia coli and showed minimal tendency for aggregation. Further detailed mutational analysis showed that each of the variants included unique combinations of non-intuitive mutations, which proved essential for performance.
“LabGenius successfully delivered an exciting and innovative example of NANOBODY® optimisation using ML. This perfectly complements Sanofi’s Large Molecule Research strategy to infuse all aspects of biologics discovery and development with the latest in computation and AI,” says Sanofi’s Global Head of Digital and Biologics Strategy and Innovation, Maria Wendt.
Speaking about the partnership’s success, LabGenius’ Chief Scientific Officer, Dr. Gino Van Heeke said, “Lead optimisation is a critical part of the antibody discovery process, and these impressive results continue to demonstrate the platform’s potential to accelerate the development of molecules with unique and important properties.”
“We’re delighted with the outcome of this research collaboration,” said Dr. James Field, Founder and CEO of LabGenius.“These results further validate our platform’s unique capabilities, and we believe that continued efforts in this area will ultimately translate into a positive outcome for patients.”
About LabGenius
Headquartered in London, LabGenius is a next-generation antibody discovery company that combines synthetic biology, robotic automation and machine learning to accelerate the development of high performing therapeutics.
LabGenius is actively pursuing a wholly-owned pipeline of immunotherapies for the treatment of solid tumours and recently published research showcasing its ability to discover best-in-class immune cell engagers.
In addition, LabGenius works with partners to leverage its ML-driven discovery platform across a range of antibody formats and therapeutic areas.
For more information, please visit www.labgeni.us, or connect on Twitter, LinkedIn and Medium.
For more information, please contact:
Media enquiries:
Communications Lead
Lucy Shaw
press@labgeni.us
Business development:
Business Development Manager
Tonya Frolov
partnerships@labgeni.us